DiscoverX Corporation, a supplier of innovative cell-based assays and services for drug discovery and development, today announced their partnership with B'SYS GmbH to expand DiscoverX's SAFETYscan in vitro pharmacological profiling services for ion channel assays. SAFETYscan services provide scientists an advanced platform to identify undesirable off-target effects of drug candidates early in the discovery and development process.
Gaining a better understanding of the safety profile of drug candidates early is crucial to reduce safety-related attrition. DiscoverX's SAFETYscan in vitro pharmacological profiling services offer functional assays to identify potential adverse events before expensive animal studies or clinical trials. The functional readouts significantly reduce false positives, saving time and resources for follow up studies. Owing to the prominent physiological roles of ion channels in cellular excitation, ion channels are important targets to be included for off-target screening. By partnering with ion channel patch-clamp experts, B'SYS, DiscoverX now offers drug developers SAFETYscan ion channel safety profiling services for both fluorescence assays and the gold standard patch clamp service. With over 13 years of experience, originating from GLP services, B'SYS offers a broad portfolio of high quality ion channel patch-clamp assays.
"By partnering with B'SYS, DiscoverX solidifies its position as the leading provider of safety profiling services for the drug discovery industry with a comprehensive menu of supported targets, including the very important ion channels," stated Todd R. Nelson, Ph.D., CEO of DiscoverX. Daniel Konrad, CEO of B'SYS, stated, "We are excited about the partnership with DiscoverX, a world-class service provider, to expand our reach to serve the global market with patch-clamp ion channel services."